Oculis’ Post

#Researchers, there is a pressing need to develop efficient, long-lasting drug delivery systems in ophthalmology, that reduce patient discomfort and increase compliance. With this call for proposals, we invite you to explore and progress drug delivery systems for inner eye administration, with a particular focus on implantable/injectable formulation approaches and applicators. The goal is to create systems capable of maintaining therapeutic drug levels for at least three months, thereby reducing the frequency of drug administration. Discover more on our open science portal #opnMe:   https://lnkd.in/ePD7w4Ag  

#Researchers, there is a pressing need to develop efficient, long-lasting drug delivery systems in ophthalmology, that reduce patient discomfort and increase compliance. With this call for proposals, we invite you to explore and progress drug delivery systems for intravitreal administration, with a particular focus on implantable/injectable formulation approaches and applicators. The goal is to create systems capable of maintaining therapeutic drug levels for at least three months, thereby reducing the frequency of drug administration. Discover more on #opnMe https://lnkd.in/ej2VPV6Z

🧑💼 The Business of Biotech (2nd Edition): Gatekeepers Of Innovation 🏛️ The Food and Drug Administration (FDA) is a formidable force in the biotech industry. Here’s what it takes to be successful and avoid common mistakes that leave drug development programs stuck in the regulatory mud. ⚔️ Gatekeeper Of Innovation Traditionally, the FDA has been revered as the protector of public health and the adversary of unethical medicine. But that does not mean that it is beyond scrutiny. Congress (and the public) frequently flips between criticism of the FDA for granting approvals too quickly and then retracts and disapproves of delayed approval rates. In recent years, the public has been increasingly skeptical of the Administration as the complexity of the political relationships between other government agencies and the private sector grows. To the pharmaceutical industry, the FDA is a powerful gatekeeper that can make or break their business. The value of public and private clinical-stage companies is wholly dependent on clinical trial data and the FDA’s final stamp of approval. Clearly, intimate knowledge of the regulatory process is an absolute must for every biotech. Understand the FDA approval process like a biotech CEO: https://lnkd.in/eFZ4Uy6F #biotechnology #arthritis #osteoarthritis #investing #crowdfunding #venturecapital #healthcare #drugdevelopment #clinicaltrials #regenerativemedicine #orthopedics #orthopaedics #surgery #investor #FDA #medicine #lifesciences #researchanddevelopment #capitalmarkets

Are you facing challenges with your clinical trial timelines or searching for a reliable, experienced CRO partner? At Altasciences, we understand the importance of streamlining your drug development process while ensuring the highest quality results. We provide a comprehensive, North American solution that can significantly enhance your clinical trials. Have a look at these resources: 1- Podcast—Benefits of Conducting a Clinical Trial in Canada: https://lnkd.in/gjgVUmMq 2- Video—Follow Your Sample From the Clinic to the Lab: https://lnkd.in/gTXfp_Mp 3- The Altascientist—Phase I Ethnobridging Clinical Trials: https://lnkd.in/gTAD8y9x 4- The Altascientist—Studying the Effects of Drugs on Driving: https://lnkd.in/gC6ngXHp 5- The Altascientist—Human Abuse Potential Studies: https://lnkd.in/gJnzJZpC 6- Video—Specialized Ophthalmology Expertise: https://lnkd.in/giPybUAb #ClinicalTrials #DrugDevelopment #ResearchAndDevelopment

#Researchers, there is a pressing need to develop efficient, long-lasting drug delivery systems in ophthalmology, that reduce patient discomfort and increase compliance. With this call for proposals, we invite you to explore and progress drug delivery systems for intravitreal administration, with a particular focus on implantable/injectable formulation approaches and applicators. The goal is to create systems capable of maintaining therapeutic drug levels for at least three months, thereby reducing the frequency of drug administration. Discover more on #opnMe https://lnkd.in/ecNCRAEr #OpenScience #Boehringer

US fast track drug development news from Market Scope: Priovant Therapeutics, of Durham, North Carolina, reported Sept. 23 that the US FDA had granted fast track designation for #brepocitinib in non-infectious intermediate or posterior uveitis or panuveitis. Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1 under evaluation for multiple autoimmune diseases. It is administered as a once-daily oral therapy. #uveitis #retina #developmentpipeline #fasttrack

Here's the first in our series of Patient Voice, real patient stories about what it's like to live with various conditions. Empathy is a core value of Patient Panorama at Healthcare Research Worldwide (HRW) and these stories help keep us grounded, remembering why we do what we do!

#Open #Angle #Glaucoma #Market Growth, Overview with Detailed Analysis 2023-2029 𝐆𝐞𝐭 𝐚 𝐝𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐚𝐧𝐚𝐥𝐲𝐬𝐢𝐬..!!https://lnkd.in/d98A9KsF Market Dynamics and Competitive Landscape Key drivers of market growth include #heightened awareness about eye health, advancements in medical technology, and significant investment in research and #development. Innovations in diagnostic tools and treatment methods, such as minimally invasive #surgical procedures and novel pharmaceutical developments, are enhancing patient outcomes and driving demand. Technological Advancements: A Key Growth Driver Technological advancements are #revolutionizing glaucoma management. Optical coherence tomography (OCT) and advanced visual field testing have improved early #detection and monitoring. Treatment has also seen significant progress with minimally invasive #glaucoma surgeries (MIGS) and sustained-release drug #delivery systems, enhancing efficacy and patient compliance. Market Segmentation Insights By Type: The market is primarily #segmented into open-angle and angle-closure glaucoma, with the former being the most prevalent. By Drug Class: #Prostaglandins, particularly effective in reducing intraocular pressure, dominated the market in 2022. #Combination drugs are also gaining traction for their synergistic effects. Regional Market Insights North America holds a significant #market share, driven by advanced healthcare #infrastructure and high glaucoma prevalence. The Asia Pacific region is emerging rapidly due to its #large population, increasing healthcare expenditure, and improving healthcare infrastructure. Key Players: Glaukos Corporation - REICHERT Kommunikationstechnik Diopsys QuidelOrtho Praxisgemeinschaft Dres. Peter Ivan Ivantis Peter Kenedi und Thomas Koch #HealthcareInnovation #MedicalResearch #Pharmaceuticals #MedicalDevices #EyeCare #HealthcareMarket #VisionCare

🔍 Wet Age-Related Macular Degeneration (Wet AMD) is a leading cause of irreversible #blindness globally, mainly affecting those over 60. Globally, about 3.5 million people are affected. Despite advancements, there are still significant unmet needs in treatment and healthcare systems. - Limited access to specialized care - Long patient wait times - High treatment burdens and costs - Need for longer-lasting treatments 🌍 Anti-VEGF are mainstay treatments for wet AMD, new class of treatments are emerging in the pipeline. Understanding how to differentiate those drugs is key for success. 🌍 Several deals in the field of Ophthalmology/Wet AMD demonstrate the interest from pharma in an area of high unmet need, leaving room and space for new agents. [Sandoz & Coherus BioSciences | Astellas Pharma & Iveric Bio, An Astellas Company | AbbVie & REGENXBIO Inc. | Biogen & Samsung Bioepis ...] If you are interested to hear more about opportunities in the field of Wet AMD, please contact us! contact@genchrome.com #wetamd #unmetneeds #pharma #biotech #ophthalmology

When you combine SAM mechnobiology with PRP autologous tissues for the treatment of soft tissue lesions, patients heal faster and return to work more quickly. Treat daily, heal faster, recover stronger. No pharmacology involvement. #innovation #partnership #madeintheusa